#1
|
||||
|
||||
Çàêîí ïàðíûõ ñëó÷àåâ.
Ñåãîäíÿ. Äâå ìîëîäûå æåíùèíû 17 è 20 ëåò, ïåðâàÿ áåðåìåííîñòü, ó îáåèõ HBsAg+, HBeAg+, ÄÍÊ âèðóñà ãåïàòèòà  +, êîëè÷åñòâåííî >110 000 000 IU/ml, ALT - íîðìà. Ðèñê âíóòðèóòðîáíîãî çàðàæåíèÿ 70-90%.
Ó ïåðâîé (17ëåò) íåïîëíûå 5 ìåñÿöåâ, ó âòîðîé (20ëåò) -10 íåäåëü. ×òî ðåêîìåíäîâàòü, êîëëåãè?
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#2
|
|||
|
|||
À ÷òî òóò ïîðåêîìåíäóåøü - âûáîð æåñòêî îãðàíè÷åí.
Óáåäèòüñÿ (òîëüêî äëÿ ëè÷íîãî ñïîêîéñòâèÿ - ALT-N), ÷òî íåò êîèíôåêöèè HEV. Îòñóòñòâèå ãèïåðòðàíñôåðàçåìèè ïîçâîëÿåò ðàññìàòðèâàòü ïðåðûâàíèå áåðåìåííîñòè (÷òî ìíå ëè÷íî âèäåòñÿ êàê âûáîð â ýòèõ ñëó÷àÿõ). Ïðàêòè÷åñêè âñå ïðîòèâîâèðóñíûå ïðåïàðàòû êëàññà Ñ, êðîìå Telbivudine (B). Òàê ÷òî, êðîìå ïîäðîáíîãî îáñóæäåíèÿ ñ ïàöèåíòêàìè èõ øàíñîâ è âîçìîæíîñòåé (ñ ó÷åòîì èõ ìîëîäîãî âîçðàñòà) íè÷åãî è íåò. |
#3
|
||||
|
||||
Íè÷åãî íå ðåêîìåíäîâàòü. Ñîîáùèòü îáåèì îá óðîâíå ðèñêà, ðàññêàçàòü î ïîñëåäñòâèÿõ äëÿ ðåáåíêà, è ïóñòü ñàìè ðåøàþò.
__________________
Åëåíà Åâãåíüåâíà Êîðíàêîâà, ïàðàçèòîëîã. |
#4
|
||||
|
||||
Âñå ýòî ñäåëàë, îáúÿñíèë ìóæüÿì. Ñ 10-íåäåëüíîé áåðåìåííîñòüþ ïðîùå. À êàê ñ 5-ìåñÿ÷íîé þðèäè÷åñêè îôîðìëÿòü? Ãåïàòèò  íå ÿâëÿåòñÿ áåçóñëîâíûì ïîêàçàíèåì ê ïðåðûâàíèþ áåðåìåííîñòè.  êàêîé ôîðìå (ïðè ñîãëàñèè ñóïðóãîâ) ñëåäóåò îôîðìëÿòü þðèäè÷åñêè? Ãèíåêîëîãè ìîãóò ïîïðîñèòü ïèñüìåííîãî çàêëþ÷åíèÿ èíôåêöèîíèñòà.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#5
|
|||
|
|||
An option for highly viraemic
Xu, WM, Cui, CYT, Wang, L, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicentre, randomised, double-blind, placebo-controlled study (abstract). Hepatology 2004; 40 (Suppl1); 272A.
19 TI Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. AU van Zonneveld M; van Nunen AB; Niesters HG; de Man RA; Schalm SW; Janssen HL SO J Viral Hepat. 2003 Jul;10(4):294-7. Vertical transmission of hepatitis B virus (HBV) can occur occasionally despite vaccination of the child. This vaccination breakthrough has been associated with high maternal viraemia. We treated eight highly viraemic (HBV-DNA >/= 1.2 x 10(9) geq/mL) mothers with 150 mg of lamivudine daily during the last month of pregnancy. HBV-DNA, hepatitis B surface antigen (HBsAg), anti-HBs and anti-HBc of their offspring were measured at birth and at 3, 6 and 12 months, respectively. Twenty-four children, born to untreated HBsAg-positive mothers with HBV-DNA levels >/=1.2 x 10(9) geq/mL served as historical controls. All children received passive-active immunization at birth and were followed-up for 12 months. In the lamivudine group one of the eight children (12.5%) was still HBsAg and HBV-DNA positive at the age of 12 months. All other children seroconverted to anti-HBs and maintained seroprotection. In three children, HBV-DNA was temporarily detected by polymerase chain reaction. In the untreated historical control group, perinatal transmission occurred in seven of 25 children (28%). In highly viraemic HBsAg-positive mothers, reduction of viraemia by lamivudine therapy in the last month of pregnancy may be an effective and safe measure to reduce the risk of child vaccination breakthrough. This approach should be evaluated in a large controlled trial. |
#6
|
|||
|
|||
Ìîãóò áûòü çàêîíîäàòåëüíûå ðàçíî÷òåíèÿ ìåæäó íàøèìè ñòðàíàìè (âîò óæ íå äóìàë, ÷òî äîæèâó äî òàêîãî).
Îôîðìëÿòü êîíñèëèóìîì. Ïðåäâàðèòåëüíî ïðîâåñòè áåñåäó ñ ãèíåêîëîãàìè (èç ñîâåòñêîãî ïðîøëîãî îíè ìîãóò áîÿòüñÿ ïîäõîäèòü ê ãåïàòèòíûì ïàöèåíòêàì, îæèäàÿ èõ "êàòàñòðîôè÷åñêîãî óõóäøåíèÿ") - íåò îñòðåéøåé ôàçû, íåò ïå÷åíî÷íîé íåäîñòàòî÷íîñòè (áèîõèìè÷åñêîãî îáîñòðåíèÿ). Ïðèâåñòè ìíîãî öèôð. |
#7
|
||||
|
||||
Ñïàñèáî çà îòêëèê, êîëëåãè. Àíòîí, â ïîñëåäíåì òðèìåñòðå ëàìèâóäèí ðàçðåøåí, ÿ çíàþ. Íî çäåñü âèðóñíàÿ íàãðóçêà íå ïðîñòî âûñîêàÿ, à çàïðåäåëüíî âûñîêàÿ. Åñëè ïåðåâîäèòü â êîïèè/ìë, òî ýòè >110ìëí Õ 5,8 = >638ìëí/ìë, à æäàòü äî ïîñëåäíåãî òðèìåñòðà åùå äîëãî èëè î÷åíü äîëãî. Ýòî êîíå÷íî âàðèàíò íà ñëó÷àé îòêàçà ïðåðûâàòü. Ññûëêà âàæíàÿ!
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#8
|
||||
|
||||
Äìèòðèé, ó íàñ â öåíòðå, ïî ñ÷àñòüþ, ðàáîòàåò âìåíÿåìûé ãèíåêîëîã. Îíà-òî êàê ðàç íå áîèòñÿ, íî íàáëþäàåò êàê ðàç òó, ó êîòîðîé ìàëûé ñðîê. Ñ ýòèì âðà÷îì ÿ ïåðåãîâîðèë. Ïîäñòðàõîâûâàþñü â îòíîøåíèè äðóãîé ïàöèåíòêè.
Çàêîíîäàòåëüíûõ ðàñõîæäåíèé íåò. Ïîòîìó, ÷òî íåò ó íàñ ïîêà íèêàêèõ íîðìàòèâíûõ àêòîâ ïî âåäåíèþ ïàöèåíòîâ ñ âèðóñíûìè ãåïàòèòàìè Â è Ñ. Ìû ñ êîëëåãàìè ïîñëåäíèå äâà ìåñÿöà èõ ïèøåì ïî çàäàíèþ ÌÇ. Îðèåíòèðóåìñÿ íà çàðóáåæíûå ãàéäû, êîòîðûå íèêòî íå çàïðåùàë, íî è íå óòâåðæäàë.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#9
|
|||
|
|||
Äîðîãîé Þñèô, äåðæèòå íàñ, ïî âîçìîæíîñòè, â êóðñå ýòîé ïàðû.
|
#10
|
||||
|
||||
Ïîñòàðàþñü, ñàìîìó èíòåðåñíî.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#11
|
||||
|
||||
Àêòèâíî ïîèíòåðåñîâàëñÿ.
Çâîíèë ìóæ 17-ëåòíåé (áåðåìåííîñòü 5 ìåñ.), ñàì ïàöàí åùå. "Íàø çíàêîìûé õèðóðã ãîâîðèò, ÷òî âñå ýòî - ãëóïîñòè, êåñàðíó â 6-7 ìåñÿöåâ, âñå áóäåò íîðìàëüíî, ïàòàìóøòî ðåáåíêó ïåðåäàåòñÿ îò ìàòåðè òîëüêî â åñòåñòâåííûõ ðîäàõ". ß ïðåäëîæèë äîãîâîðèòüñÿ, ÷òî â ñëó÷àå íàëè÷èÿ èíôåêöèè ó íîâîðîæäåííîãî, åòîò äîêòîð åãî ëå÷åíèå áåðåò ñî âñåé îòâåòñòâåííîñòüþ íà ñåáÿ. Äðóãàÿ ïàöèåíòêà ïîêà âíå ïîëÿ çðåíèÿ.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#12
|
|||
|
|||
óâàÿåìè Þñèô!ìíå êàæåòñà âè ìîæåòå òîëêî ðåêîìåíäîâàò ,ïîòîìó ÷òî íåò 100%-ãî ðèñêà ïåðåäà÷ îò ìàòåðè ê ðåáèîíêó.åñëè åòî ïåðâàèà áåðåìåííîñò è ïîñëå ïåðâîãî àáîðòà ó åòîè ñåìè íå áóäåò äåòåè òî îíè ,,èà òàê äóìàèó" âñèó éèçí áóäóò âàñ ïðåñëåäîâàò.
|
#13
|
||||
|
||||
ß òàê è ñäåëàë, íî ê êîíñóëüòàöèè ïîäêëþ÷èë è ãèíåêîëîãà, ÷òîáû íå áðàòü íà ñåáÿ èçëèøíþþ îòâåòñòâåííîñòü.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |